Allan-Herndon-Dudley Syndrome.

Area of Science:

• Genetics
• Endocrinology
• Neurology

Background:

• X-linked MCT 8 mutations are the primary cause of Allan-Herndon-Dudley syndrome (AHDS).
• AHDS is characterized by severe developmental delay, hypotonia, and unique thyroid function abnormalities.
• Impaired thyroid hormone transport and sensitivity are key features of the syndrome.

Purpose of the Study:

• To report a case of Allan-Herndon-Dudley syndrome diagnosed in a young boy.
• To identify the genetic mutation responsible for the observed clinical presentation.
• To evaluate the therapeutic effect of triiodoacetic acid on neurodevelopmental and biochemical features.

Main Methods:

• Clinical assessment of a 2-year-old boy with severe developmental delay and hypotonia.
• Biochemical analysis of thyroid function tests (FT3, FT4, TSH).
• Whole exome sequencing (WES) to identify genetic mutations in the MCT 8 gene.

Main Results:

• The patient presented with severe developmental delay, hypotonia, and thyroid profile indicative of impaired thyroid hormone sensitivity (high FT3, low FT4, normal TSH).
• Whole exome sequencing identified a novel mutation in exon 3 of the MCT 8 gene.
• Treatment with triiodoacetic acid led to improvements in neurodevelopmental delay and thyrotoxicosis features.

Conclusions:

• This case highlights the genetic basis of AHDS and the diagnostic utility of WES.
• Triiodoacetic acid shows promise as a therapeutic agent for Allan-Herndon-Dudley syndrome.
• Targeting thyroid hormone transport offers a potential treatment strategy for AHDS.